Metabolic labeling and targeted modulation of dendritic cells
Source abstract
Abstract
Targeted immunomodulation of dendritic cells (DCs) in vivo will enable manipulation of T-cell priming and amplification of anticancer immune responses, but a general strategy has been lacking. Here we show that DCs concentrated by a biomaterial can be metabolically labelled with azido groups in situ, which allows for their subsequent tracking and targeted modulation over time. Azido-labelled DCs were detected in lymph nodes for weeks, and could covalently capture dibenzocyclooctyne (DBCO)-bearing antigens and adjuvants via efficient Click chemistry for improved antigen-specific CD8+ T-cell responses and antitumour efficacy. We also show that azido labelling of DCs allowed for in vitro and in vivo conjugation of DBCO-modified cytokines, including DBCO-IL-15/IL-15Rα, to improve priming of antigen-specific CD8+ T cells. This DC labelling and targeted modulation technology provides an unprecedented strategy for manipulating DCs and regulating DC-T-cell interactions in vivo.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Cancer Research and Treatments · CAR-T cell therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (53)
Show source-provided references
1. Laughlin, S. T. & Bertozzi, C. R. Metabolic labeling of glycans with azido sugars and subsequent glycan-profiling and visualization via staudinger ligation. Nat. Protoc. 2, 2930 (2007).10.1038/nprot.2007.422 ↗
2. Laughlin, S. T. et al. Metabolic labeling of glycans with azido sugars for visualization and glycoproteomics. Methods Enzymol. 415, 230–250 (2006).10.1016/S0076-6879(06)15015-6 ↗
3. Chang, P. V. et al. Copper-free click chemistry in living animals. Proc. Natl Acad. Sci. USA 107, 1821–1826 (2010).10.1073/pnas.0911116107 ↗
4. Baskin, J. M. et al. Copper-free click chemistry for dynamic in vivo imaging. Proc. Natl Acad. Sci. USA 104, 16793–16797 (2007).10.1073/pnas.0707090104 ↗
5. Wang, H. et al. Targeted ultrasound-assisted cancer-selective chemical labeling and subsequent cancer imaging using click chemistry. Angew. Chem. Int. Ed. 55, 5452–5456 (2016).10.1002/anie.201509601 ↗
6. Wang, H. et al. In vivo cancer targeting via glycopolyester nanoparticle mediated metabolic cell labeling followed by click reaction. Biomaterials 218, 119305 (2019).10.1016/j.biomaterials.2019.119305 ↗
7. Lee, S. et al. Chemical tumor-targeting of nanoparticles based on metabolic glycoengineering and click chemistry. ACS Nano 8, 2048–2063 (2014).10.1021/nn406584y ↗
8. Du, L., Qin, H., Ma, T., Zhang, T. & Xing, D. In vivo imaging-guided photothermal/photoacoustic synergistic therapy with bioorthogonal metabolic glycoengineering-activated tumor targeting nanoparticles. ACS Nano 11, 8930–8943 (2017).10.1021/acsnano.7b03226 ↗
9. Li, X., Xu, X., Rao, X., Tian, Y. & Yi, W. Chemical remodeling cell surface glycans for immunotargeting of tumor cells. Carbohydr. Res. 452, 25–34 (2017).10.1016/j.carres.2017.10.003 ↗
10. Le Gall, C. M., Weiden, J., Eggermont, L. J. & Figdor, C. G. Dendritic cells in cancer immunotherapy. Nat. Mater. 17, 474–475 (2018).10.1038/s41563-018-0093-6 ↗
11. Sallusto, F. et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur. J. Immunol. 29, 1617–1625 (1999).10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3 ↗
12. Liu, Y.-J. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106, 259–262 (2001).10.1016/S0092-8674(01)00456-1 ↗
13. Merad, M., Sathe, P., Helft, J., Miller, J. & Mortha, A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31, 563–604 (2013).10.1146/annurev-immunol-020711-074950 ↗
14. De Vries, I. J. M. et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol. 23, 1407–1413 (2005).10.1038/nbt1154 ↗
15. Rhee, I., Zhong, M.-C., Reizis, B., Cheong, C. & Veillette, A. Control of dendritic cell migration, T cell-dependent immunity, and autoimmunity by protein tyrosine phosphatase PTPN12 expressed in dendritic cells. Mol. Cell Biol. 34, 888–899 (2014).10.1128/MCB.01369-13 ↗
16. Ahrens, E. T. & Bulte, J. W. Tracking immune cells in vivo using magnetic resonance imaging. Nat. Rev. Immunol. 13, 755–763 (2013).10.1038/nri3531 ↗
17. Bertozzi, C. R. & Kiessling, L. Chemical glycobiology. Science 291, 2357–2364 (2001).10.1126/science.1059820 ↗
18. Luchansky, S. J. et al. in Methods of Enzymology Vol. 362 (eds Lee Yuan, C. & Lee Reiko, T.) 249–272 (Academic Press, 2003).10.1016/S0076-6879(03)01018-8 ↗
19. Prescher, J. A. & Bertozzi, C. R. Chemistry in living systems. Nat. Chem. Biol. 1, 13–21 (2005).10.1038/nchembio0605-13 ↗
20. Kang, S.-W. et al. Cell labeling and tracking method without distorted signals by phagocytosis of macrophages. Theranostics 4, 420–431 (2014).10.7150/thno.7265 ↗
21. Verbeke, C. S. & Mooney, D. J. Injectable, pore-forming hydrogels for in vivo enrichment of immature dendritic cells. Adv. Healthc. Mater. 4, 2677–2687 (2015).10.1002/adhm.201500618 ↗
22. Verbeke, C. S. et al. Multicomponent injectable hydrogels for antigen-specific tolerogenic immune modulation. Adv. Healthc. Mater. 6, https://doi.org/10.1002/adhm.201600773 (2017).10.1002/adhm.201600773 ↗
23. Wang, H. et al. In vivo targeting of metabolically labeled cancers with ultra-small silica nanoconjugates. Theranostics 6, 1467–1476 (2016).10.7150/thno.16003 ↗
24. Kearney, C. J. et al. Switchable release of entrapped nanoparticles from alginate hydrogels. Adv. Healthc. Mater. 4, 1634–1639 (2015).10.1002/adhm.201500254 ↗
25. Kamath, A. T., Henri, S., Battye, F., Tough, D. F. & Shortman, K. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 100, 1734–1741 (2002).10.1182/blood.V100.5.1734.h81702001734_1734_1741 ↗
26. Randolph, G. J., Angeli, V. & Swartz, M. A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 5, 617–628 (2005).10.1038/nri1670 ↗
27. Wang, H. et al. Selective in vivo metabolic cell-labeling-mediated cancer targeting. Nat. Chem. Biol. 13, 415–424 (2017).10.1038/nchembio.2297 ↗
28. Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4, 11–22 (2004).10.1038/nrc1252 ↗
29. Motzer, R. J. et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18, 1928–1935 (2000).10.1200/JCO.2000.18.9.1928 ↗
30. Waldmann, T. A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6, 595–601 (2006).10.1038/nri1901 ↗
31. Sato, N., Patel, H. J., Waldmann, T. A. & Tagaya, Y. The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc. Natl Acad. Sci. USA 104, 588–593 (2007).10.1073/pnas.0610115104 ↗
32. Stoklasek, T. A., Schluns, K. S. & Lefrançois, L. Combined IL-15/IL-15Rα immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177, 6072–6080 (2006).10.4049/jimmunol.177.9.6072 ↗
33. Ferlazzo, G. et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl Acad. Sci. USA 101, 16606–16611 (2004).10.1073/pnas.0407522101 ↗
34. Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692–696 (2015).10.1038/nature14426 ↗
35. Epardaud, M. et al. Interleukin-15/Interleukin-15Rα complexes promote destruction of established tumors by reviving tumor-resident CD8+ T Cells. Cancer Res. 68, 2972–2983 (2008).10.1158/0008-5472.CAN-08-0045 ↗
36. Bonifaz, L. C. et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199, 815–824 (2004).10.1084/jem.20032220 ↗
37. Tacken, P. J., de Vries, I. J. M., Torensma, R. & Figdor, C. G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7, 790–802 (2007).10.1038/nri2173 ↗
38. Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519–522 (2014).10.1038/nature12978 ↗
39. Reddy, S. T., Rehor, A., Schmoekel, H. G., Hubbell, J. A. & Swartz, M. A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 112, 26–34 (2006).10.1016/j.jconrel.2006.01.006 ↗
40. Tomura, M. et al. Monitoring cellular movement in vivo with photoconvertible fluorescence protein ‘Kaede’ transgenic mice. Proc. Natl Acad. Sci. USA 105, 10871–10876 (2008).10.1073/pnas.0802278105 ↗
41. Tomura, M. et al. Tracking and quantification of dendritic cell migration and antigen trafficking between the skin and lymph nodes. Sci. Rep. 4, 6030 (2014).10.1038/srep06030 ↗
42. Alvarez, D., Vollmann, E. H. & von Andrian, U. H. Mechanisms and consequences of dendritic cell migration. Immunity 29, 325–342 (2008).10.1016/j.immuni.2008.08.006 ↗
43. Ichihashi, M. et al. UV-induced skin damage. Toxicology 189, 21–39 (2003).10.1016/S0300-483X(03)00150-1 ↗
44. Chang, P. V., Dube, D. H., Sletten, E. M. & Bertozzi, C. R. A strategy for the selective imaging of glycans using caged metabolic precursors. J. Am. Chem. Soc. 132, 9516–9518 (2010).10.1021/ja101080y ↗
45. Hanson, M. C. et al. Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants. J. Clin. Invest. 125, 2532–2546 (2015).10.1172/JCI79915 ↗
46. Mueller, S. N., Tian, S. & DeSimone, J. M. Rapid and persistent delivery of antigen by lymph node targeting PRINT nanoparticle vaccine carrier to promote humoral immunity. Mol. Pharm. 12, 1356–1365 (2015).10.1021/mp500589c ↗
47. Wang, Q., Cao, W., Yang, Z.-G. & Zhao, G.-F. DC targeting DNA vaccines induce protective and therapeutic antitumor immunity in mice. Int. J. Clin. Exp. Med. 8, 17565–17577 (2015).
48. Cruz, L. J. et al. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: a comparative study. J. Control. Release 192, 209–218 (2014).10.1016/j.jconrel.2014.07.040 ↗
49. Cheong, C. et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 116, 3828–3838 (2010).10.1182/blood-2010-06-288068 ↗
50. Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).10.1038/nature23003 ↗
51. Wang, H. & Mooney, D. J. Biomaterial-assisted targeted modulation of immune cells in cancer treatment. Nat. Mater. 17, 761–772 (2018).10.1038/s41563-018-0147-9 ↗
52. Melero, I. et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509–524 (2014).10.1038/nrclinonc.2014.111 ↗
53. Hodi, F. S. Dendritic cell activating scaffold in melanoma. ClinicalTrials.org https://clinicaltrials.gov/show/nct01753089 (2017).